KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Intangibles (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Intangibles for 6 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles changed N/A year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $4.4 million, changed N/A over the prior year.
  • Intangibles was $3.9 million for Q3 2025 at Aurinia Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $8.9 million in Q3 2021 and bottomed at $3.9 million in Q3 2025.
  • Average Intangibles over 5 years is $6.1 million, with a median of $6.1 million recorded in 2023.
  • The sharpest move saw Intangibles dropped 23.55% in 2022, then decreased 21.98% in 2024.
  • Year by year, Intangibles stood at $8.4 million in 2021, then fell by 23.55% to $6.4 million in 2022, then decreased by 5.04% to $6.1 million in 2023, then fell by 28.62% to $4.4 million in 2024, then fell by 10.42% to $3.9 million in 2025.
  • Business Quant data shows Intangibles for AUPH at $3.9 million in Q3 2025, $4.4 million in Q4 2024, and $4.6 million in Q2 2024.